Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Synthesis of 2-(Quinoxalin-2-yl)acetamides and Their Preliminary Cytotoxic and Antibacterial Activity.

Created on 18 Jan 2026

Authors

Cesar E Tovar-Roman, Eduardo Hernández-Vázquez, José A Rivera-Chávez

Published in

Chemistry & biodiversity. Volume 23. Issue 1. Pages e03511.

Abstract

Quinoxaline is an aza-heterocycle found in some bioactive compounds. Thus, to enhance the pharmacological scope of this nucleus, we report a series of 19 acetamides decorated with a quinoxaline core. The synthesis involved the linkage of previously constructed bromoacetamides and hydroxyphenyl quinoxalines via an SN2 reaction. The first series considered a 1,4-substituted phenyl ring as a linker, and some derivatives showed moderate antibacterial activity against a panel of ESKAPE pathogens, especially against methicillin-resistant Staphylococcus aureus (inhibition ranging from 10% to 60% at 100 µM). Interestingly, the activity dropped in the 1,3- and 1,2-regioisomers. Furthermore, we tested the series against relevant human cancer cell lines, in which the ethyl derivative 10c inhibited the growth of breast, prostate, and colon tumors (43%, 48%, and 66%, respectively), whereas COS-7 cells showed only 7.8% inhibition. Although these are preliminary in vitro findings, we corroborate the applicability of the quinoxaline heterocycle in the design of potential candidates against relevant pathologies.

PMID:
41548064
Bibliographic data and abstract were imported from PubMed on 18 Jan 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement